European Commission clears Novozymes, Chr. Hansen merger
Reuters
Published Dec 12, 2023 15:39
PARIS (Reuters) -The European Commission said in a statement on Tuesday it had cleared the merger between Danish food ingredients and enzymes makers Novozymes and Chr. Hansen, subject to conditions.
Reuters reported on Dec. 6, based on sources, that the companies were expected to get EU antitrust approval for their all-share $22 billion tie-up, based on remedies offered to address competition concerns.
Novozymes, which makes enzymes for household products, food and beverages and biofuels, and Chr. Hansen, an enzyme maker for the food sector, last month offered to sell part of the combined company's global lactase enzyme business, saying that a buyer had already been found.
The deal, the largest merger in Denmark, would create a global ingredients giant.
The Commission said its merger approval is conditional upon full compliance with the commitments offered by the parties.
It said that its investigation had showed that the merger, as initially notified, would have reduced competition in the market for the manufacture of one specific enzyme, lactase, using genetic modification technology.
In particular, the Commission found that Chr Hansen had a project to start manufacturing this product and would very likely grow into an effective competitor within a short timeframe. The Commission also found that post-merger there would not be sufficient potential competitors to exert sufficient competitive pressure on the merged entity.
The Commission said that in order to address its concerns, the parties offered to divest Chr. Hansen's project to enter the market for the manufacture of lactase; Chr. Hansen's lactase distribution business; Novozymes' lactase production facility.
"These commitments fully address the competition concerns identified by the Commission, by paving the way for the creation of a divested business with the necessary production assets and research and development capabilities to grow as a viable competitive producer of lactase on a lasting basis," it said.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.